Oncogenic HRAS Induces Metformin Resistance in Head and Neck Cancer by Promoting Glycolytic Metabolism
Xingyu Wu(Southwest University), J. Silvio Gutkind(National Institutes of Health), Thomas S. Hoang(University of California San Diego), Kuniaki Sato(University of California San Diego), Pham Thuy Tien Vo(University of California San Diego), Keiichi Koshizuka(Chiba University), Kris C. Wood(Duke University), Michael M. Allevato(University of California San Diego), Scott M. Lippman(UC San Diego Health System), Hiroki Izumi(National Cancer Center Hospital East), Yusuke Goto(Chiba University), Sendi Rafael Adame-Garcia(University of California San Diego)
Cited by 3
Related Papers
Lung Cancer
|New England Journal of Medicine|2008|2.4k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Metabolic programming and PDHK1 control CD4+ T cell subsets and inflammation
|Journal of Clinical Investigation|2014|717
The emerging mutational landscape of G proteins and G-protein-coupled receptors in cancer
|Nature reviews. Cancer|2013|569